Factors Associated with Pain Following Intravitreal Injections

Seong Hwan Shin, Sung Pyo Park, Yong Kyu Kim, Seong Hwan Shin, Sung Pyo Park, Yong Kyu Kim

Abstract

Purpose: To investigate factors associated with pain intensity following intravitreal injection and factors that might be associated with changes in pain intensity in patients who received repeated injections.

Methods: A total of 172 eyes (147 patients) were prospectively enrolled. Patients rated their pain from 0 to 10 using a visual analogue scale. Multiple linear regression analysis was used to evaluate factors associated with pain score. Sixty-eight patients evaluated their degree of pain more than once and were divided into three groups according to changes in pain during repeated injections. Clinical factors were compared among the three groups.

Results: Pain scores of women (women, 3.1 ± 1.5 vs. men, 2.4 ± 1.2; p = 0.003), those who received dexamethasone implant injection (dexamethasone implant, 3.5 ± 1.1 vs. anti-vascular endothelial growth factor, 2.7 ± 1.4; p = 0.028), and those who did not undergo anterior chamber paracentesis (ACP) (ACP, 2.6 ± 1.3 vs. no ACP, 3.0 ± 1.6; p = 0.047) were significantly higher than those of the other groups. On multiple linear regression analysis, only female sex and ACP were significantly associated with degree of pain. The waiting time during the second injection was significantly associated with change in degree of pain in patients who received repeated injections.

Conclusions: Women were more prone to perceive pain, and the ACP procedure reduced pain during intravitreal injections. Most patients who received repeated injections felt that pain was similar or decreased compared to that experienced during the previous injection. However, increased waiting time might have been associated with increased discomfort for patients who received repeated injections.

Keywords: Intravitreal injections; Pain; Paracentesis; Sex; Visual analogue scale.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

© 2018 The Korean Ophthalmological Society.

References

    1. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.
    1. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658–1665.
    1. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124–1133.
    1. Davis MJ, Pollack JS, Shott S. Comparison of topical anesthetics for intravitreal injections: a randomized clinical trial. Retina. 2012;32:701–705.
    1. Rodrigues EB, Grumann A, Jr, Penha FM, et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther. 2011;27:197–203.
    1. Rifkin L, Schaal S. Shortening ocular pain duration following intravitreal injections. Eur J Ophthalmol. 2012;22:1008–1012.
    1. Hernandez-Siman J, Marra K, Arroyo J. Sub-conjunctival lidocaine injection before intravitreal injection. Surv Ophthalmol. 2014;59:672–673.
    1. Moisseiev E, Regenbogen M, Rabinovitch T, et al. Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections. Eye (Lond) 2014;28:980–985.
    1. Ulrich JN. Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial. Retina. 2014;34:509–511.
    1. Andrade GC, Carvalho AC. Comparison of 3 different anesthetic approaches for intravitreal injections: a prospective randomized trial. Arq Bras Oftalmol. 2015;78:27–31.
    1. Karabas VL, Ozkan B, Kocer CA, et al. Comparison of two anesthetic methods for intravitreal ozurdex injection. J Ophthalmol. 2015;2015:861535.
    1. Massamba N, Elluard M, Agoune W, et al. Assessment of ocular pain following ranibizumab intravitreal injection. Acta Ophthalmol. 2015;93:e231–e232.
    1. van Asten F, van Middendorp H, Verkerk S, et al. Are intravitreal injections with ultrathin 33-G needles less painful than the commonly used 30-G needles? Retina. 2015;35:1778–1785.
    1. Rifkin L, Schaal S. Factors affecting patients' pain intensity during in office intravitreal injection procedure. Retina. 2012;32:696–700.
    1. Ichiyama Y, Sawada T, Kakinoki M, et al. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration. Ophthalmic Res. 2014;52:234–238.
    1. Haas P, Falkner-Radler C, Wimpissinger B, et al. Needle size in intravitreal injections - pain evaluation of a randomized clinical trial. Acta Ophthalmol. 2016;94:198–202.
    1. Kozak I, Cheng L, Freeman WR. Lidocaine gel anesthesia for intravitreal drug administration. Retina. 2005;25:994–998.
    1. Mogil JS, Bailey AL. Sex and gender differences in pain and analgesia. Prog Brain Res. 2010;186:141–157.
    1. Knip MM, Valimaki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol. 2012;90:254–258.
    1. Katayama BY, Bonini-Filho MA, Messias AM, et al. Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. J Glaucoma. 2014;23:461–463.
    1. Ornek N, Apan A, Ornek K, Gunay F. Anesthetic effectiveness of topical levobupivacaine 0.75% versus topical proparacaine 0.5% for intravitreal injections. Saudi J Anaesth. 2014;8:198–201.
    1. Moisseiev E, Regenbogen M, Bartfeld Y, Barak A. Evaluation of pain in intravitreal bevacizumab injections. Curr Eye Res. 2012;37:813–817.
    1. Segal O, Segal-Trivitz Y, Nemet AY, et al. Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol. 2016;94:203–204.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren